Novartis Cosentyx® shows encouraging results versus Humira®* from first-of-its-kind head-to-head trial in psoriatic arthritis

    NEXT STORY
    EyePoint Pharmaceuticals Secures New Patient Access Agreement with Vizient Inc. for DEXYCU®
    PREV STORY
    Blueberries Medical Partners with 12,000 Patient Health Clinic and Renowned Academic Foundation and Announces Final Closing of Over-Subscribed Private Placement
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Aptose Biosciences Files New Preliminary Base Shelf Prospectus to Replace Expired Base Prospectus

    SAN DIEGO and TORONTO, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” ...

    author_avatar
    NASDAQ Market News

    Stemline Therapeutics Announces Three ELZONRIS™ (tagraxofusp; SL-401) Clinical Presentations, Including an Oral Presentation, at the EHA Congress

    NEW YORK, June 14, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage ...

    author_avatar
    NASDAQ Market News

    TESARO Outlines Business Priorities and Strategic Outlook for 2016

    U.S. commercial launch of VARUBI™ (oral rolapitant) well underwayData from niraparib NOVA and QUADRA ...

    author_avatar
    NASDAQ Market News